INTRODUCTION AND OBJECTIVES: Current pre-radical prostatectomy (RP) nomograms predicting lymph node involvement (LNI) are based on systematic 12-core prostate biopsies (PBx). With the introduction of multiparametric MRI (mpMRI), cognitive or fusion biopsies have become prevalent, often in the absence of systematic cores. We examine the practical application of MR biopsy data using established pre-RP nomograms and the potential implications on RP intra-operative decision making.
METHODS: Utilizing a prospectively maintained single institution database, all patients who underwent MRI-based PBx prior to RP were identified. Each patient was individually assessed using the MSKCC Kattan nomogram and the Briganti nomogram using the following iterations: 1) Targeted [T] (targeted cores alone), 2) Targeted & Systematic [TS] and 3) Targeted Augmented [TA] (Figure 1 ). The TA iteration utilized targeted core data alone and assumed negative remaining systematic cores for a total 12 core. Nomogram outcomes, specifically risk of LNI, was compared across iterations. Clinically significant impact was defined as a change in risk above or below 2% (D2) or 5% (D5), based on current guideline recommendations for lymph node dissection.
RESULTS: 69 men met inclusion criteria (6 targeted, 63 systematic þ targeted PBx). In the 6 men with targeted only biopsies, using the Kattan and Briganti nomograms, D2 occurred in 1 patient (16.7%) and D5 in 1-2 patients (16.7-33.3%); in all, TA iteration LNI was lower than the T iteration. In the 58 patients with positive targeted biopsy cores, D2 and D5 were 8.62-32.76% and 25.86-37.93%, respectively. In the subset of 52 patients with both targeted and systematic biopsies, using their TS nomogram as an internal validation, the TA iteration was a better approximation of their TS outcomes than their T iteration in 48% (Kattan) and 67% (Briganti) of patients.
CONCLUSIONS: mpMRI-based prostate biopsy results, and in particular those from targeted biopsy cores alone, yield significantly different results using established pre-RP nomograms. Therefore, future nomograms must better incorporate MRI biopsy data and provide guidelines on how to account for targeted cores. In the interim, augmenting targeted biopsy data may bridge the gap. INTRODUCTION AND OBJECTIVES: African-American men (AA) have a higher incidence of prostate cancer (PCa) and tend to have more advanced disease at presentation than white-American men (W). Little data currently exists demonstrating the effectiveness of prostate multiparametric magnetic resonance imaging (mpMRI) in this high-risk group, despite widespread adoption of mpMRI as a diagnostic tool for PCa. We aim to compare the accuracy of prostate mpMRI in AA and W men.
METHODS: We examined our prostate mpMRI database from October 2014 to June 2017 and identified 601 men who underwent 3-Tesla prostate mpMRI prior to biopsy (58 AA, 541 W). All prostate mpMRI were reported using the Prostate Imaging Reporting and Data System (PIRADS). All men received a systematic standard template prostate biopsy, and men with PIRADS classification 3 to 5 lesions underwent additional MRI targeted biopsy using the UroNav platform. For our analysis, we examined diagnostic accuracy of prostate mpMRI for detecting clinically significant PCa, treating PIRADS classification 4 or 5 as test positive and Gleason grade group (GGG) 2 or higher as clinically significant PCa. Propensity score matching was used to match 58 AA to 115 W in a 1:2 ratio by age, PSA, and PSA density.
RESULTS: In our matched comparison, average age (62.6 vs 61.9, p[0.79), PSA (9.3 vs 8.1, p[0.11), and PSA density (0.19 vs 0.16, p[0.55) 
